Chemtos Applies to Bulk Manufacture Controlled Substances
Published Date: 3/30/2026
Notice
Summary
Chemtos, LLC wants to become a big-time maker of certain controlled substances, including some strong and tightly regulated drugs. People and companies involved with these substances can share their thoughts or ask for a hearing by May 29, 2026. This move could shake up the supply chain and means Chemtos is stepping into a serious role with important deadlines and rules to follow.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Deadline to Comment or Request Hearing
Registered bulk manufacturers of the affected basic classes and applicants may submit electronic comments or objections, or request a hearing, on or before May 29, 2026. Comments must be submitted through https://www.regulations.gov and you will receive a Comment Tracking Number when your submission is accepted.
Application to Manufacture Schedule I Reference Standards
On February 13, 2026, Chemtos, LLC (Round Rock, Texas) applied to be registered as a bulk manufacturer of multiple Schedule I controlled substances, including 4-Chloromethcathinone (drug code 1239) and others listed in the notice. The company plans to bulk manufacture the listed substances for distribution as reference standards to its customers, and no other activities for these drug codes are authorized under this registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-06051 — Importer of Controlled Substances Application: Usona Institute
Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.
Next: 2026-06053 — Importer of Controlled Substances Application: Pharmaron Manufacturing Services (US) LLC
Pharmaron Manufacturing Services (US) LLC wants to become an official importer of certain controlled substances, like poppy straw concentrate. This means they’ll be allowed to bring these drugs into the U.S. Companies and manufacturers affected have until April 29, 2026, to share their thoughts or ask for a hearing. No direct money changes yet, but this could impact drug supply chains soon!